Related Experiment Video
Updated: Jun 29, 2025
11:44
Synthesis and Structure Determination of µ-Conotoxin PIIIA Isomers with Different Disulfide Connectivities
Published on: October 2, 2018
12.6K
Using Constellation Pharmacology to Characterize a Novel α-Conotoxin from Conus ateralbus
Jorge L B Neves1,2, Cristoval Urcino2, Kevin Chase2
1Interdisciplinary Centre of Marine and Environmental Research (CIIMAR/CIMAR-LA), University of Porto, Terminal de Cruzeiros do Porto de Leixões, Avenida General Norton de Matos, S/N, 4450-208 Matosinhos, Portugal.
Marine Drugs
|March 27, 2024
Summary
We discovered a new α-conotoxin (αCtx-AtIA) from Conus ateralbus that selectively targets α7 nicotinic acetylcholine receptors (nAChRs). This peptide shows potential for studying nAChRs and related neurological diseases.
Area of Science:
- Biochemistry
- Neuroscience
- Pharmacology
Background:
- Cone snail venom contains bioactive peptides targeting ion channels and receptors.
- α-Conotoxins (αCtx) are crucial tools for studying nicotinic acetylcholine receptors (nAChRs) and their role in neurological diseases.
Purpose of the Study:
- To discover and characterize a novel α-conotoxin, αCtx-AtIA, from *Conus ateralbus*.
- To investigate the nAChR subtype selectivity profile of αCtx-AtIA.
- To identify key residues contributing to αCtx-AtIA's activity.
Main Methods:
- Synthesis of αCtx-AtIA and its analogs.
- Calcium imaging-based Constellation Pharmacology assay on mouse DRG neurons.
- Two-electrode voltage clamp electrophysiology on oocytes expressing specific mouse nAChR subtypes (α3β4, α6/α3β4, α7).
Main Results:
- αCtx-AtIA selectively inhibited ACh-induced calcium influx in α7 nAChRs, particularly with the allosteric modulator PNU-120596.
- αCtx-AtIA showed low potency against α3β4 and α6/α3β4 nAChRs.
- Compared to αCtx-PeIA, αCtx-AtIA demonstrated improved potency and selectivity for α7 nAChRs.
- Residue Trp18 was identified as critical for αCtx-AtIA's activity.
Conclusions:
- αCtx-AtIA is a novel α-conotoxin with high selectivity for α7 nAChRs.
- This conotoxin serves as a valuable pharmacological tool for α7 nAChR research.
- Understanding αCtx-AtIA's interaction with nAChRs can advance insights into nAChR-associated neurological disorders.
More Related Videos
Related Concept Videos
01:29Cholinergic Antagonists: Chemistry and Structure-Activity Relationship
2.2K
Cholinergic antagonists bind to cholinergic receptors and limit the effects of acetylcholine and other cholinergic agonists. Based on the specific cholinergic receptor affinity, these antagonists are classified as muscarinic or nicotinic. Anticholinergics interrupt parasympathetic innervations while sympathetic innervations remain uninterrupted. Muscarinic antagonists are also called 'muscarinic antagonists', 'antimuscarinics', or 'parasympatholytics'. Nicotinic...
2.2K
01:29The Two-State Receptor Model
1.9K
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
The binding affinity of a drug determines its interaction with...
1.9K
01:22Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
954
Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
The direct-acting...
954
01:25Drug-Receptor Interaction: Agonist
2.5K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.5K
01:15Cholinergic Receptors: Nicotinic
2.7K
Nicotinic receptors are ligand-gated ion channels that are activated by acetylcholine and nicotine. Upon activation, they cause a rapid increase in the permeability of cells to K+, Na+, and Ca2+, followed by depolarization and excitation. They are in the autonomic ganglia, skeletal neuromuscular junction, CNS, and adrenal medulla.
There are two types of nicotinic receptors: neuromuscular (NM/NM/N1) and neuronal (NN/NN/N2). The two families differ based on their location and selectivity to...
There are two types of nicotinic receptors: neuromuscular (NM/NM/N1) and neuronal (NN/NN/N2). The two families differ based on their location and selectivity to...
2.7K
01:17Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
1.8K
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
1.8K